**
In a remarkable response to the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC), health authorities have initiated a groundbreaking treatment trial, enrolling its first patients just six weeks after the World Health Organization (WHO) declared the crisis a public health emergency on 17 May. This accelerated approach aims to test two promising drugs, offering hope amidst a dire situation that has already claimed hundreds of lives.
Rapid Response to a Dire Crisis
As of 9 July, the outbreak, caused by the Bundibugyo strain of the Ebola virus, has resulted in 1,792 confirmed cases and 625 fatalities. The speed at which these trials have been organised is unprecedented, highlighting a new urgency in the fight against this deadly virus. In Bunia, the capital of Ituri province, residents are expressing their anxieties and frustrations. Neema Haba, a local mother and banana seller, lamented, “I hope these drug trials proceed quickly. Financially, we are being driven to the brink by this outbreak and nothing is going right. We are struggling to provide for our children.”
The situation is further complicated by the challenges faced in tracing and monitoring contacts of infected individuals. WHO reports indicate that while around 75% of known contacts are being traced, a lack of trust in authorities and the mobile nature of the population severely hinder effective management. Moreover, some frontline workers have halted their efforts due to delayed payments, exacerbating the crisis.
The Challenges of Care
The safe burial of Ebola victims is another critical issue. Ovide Maliabo, a driver for a burial team in Rwampara, shared the dangers faced by his group, stating, “At one point, we narrowly escaped being lynched. It’s a shame that we aren’t being financially supported.” The lack of essential equipment and protective gear has also hampered the response, leaving many frontline workers vulnerable.
Despite these hurdles, the DRC government asserts that payments have been made to workers, though the clarity surrounding these transactions has been questioned. A local airport closure in Bunia has further complicated logistics, affecting the timely supply of necessary resources.
Promising Drug Trials Underway
In an optimistic turn, the Partners treatment trial has commenced, testing two drugs: remdesivir and MBP134. These medications will be administered to patients in varying combinations, alongside standard supportive care. Remdesivir, an antiviral developed by Gilead Sciences, and MBP134, a monoclonal antibody produced by Mapp Biopharmaceutical, have shown efficacy against the Bundibugyo virus in animal studies.
Prof Laurens Liesenborghs from the Institute of Tropical Medicine in Antwerp emphasised the importance of these trials, stating, “These two drugs actually have been proven to work against the Bundibugyo virus in animal models. They showed great efficacy, but now we need to test it in humans.” The goal is to assess whether these treatments can significantly lower mortality rates.
Historically, the Bundibugyo strain has a lower mortality rate compared to the more infamous Zaire strain; however, it still poses a serious threat, killing approximately one in three infected individuals.
Looking Ahead: A Collaborative Effort
The trial is poised to include a diverse patient demographic, with participants of all ages, including pregnant and breastfeeding women, who are often excluded from clinical research. Prof Amanda Rojek of the University of Oxford highlighted the significance of rapid initiation, stating, “It’s just fantastic we’ve managed to get started so quickly.”
This trial is not only a vital attempt to find effective treatments but also a reflection of improved scientific infrastructure in the DRC, which has previously reported lengthy delays in launching clinical trials during health crises.
Additionally, another trial is set to begin shortly, investigating the potential of a drug called obeldesivir to prevent illness in those who have been in contact with Bundibugyo cases. However, the Africa CDC has indicated that this initiative requires substantial funding, with $6 million already committed out of an estimated $18 million needed.
Why it Matters
The launch of these trials represents a beacon of hope in a region grappling with the devastating impacts of Ebola. As the DRC battles this outbreak, the swift introduction of clinical trials not only aims to save lives but also strengthens community trust in health authorities. The success of these efforts may not only mitigate the current crisis but also lay the groundwork for better preparedness and response in the face of future outbreaks, ultimately contributing to global health security.
